|
Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). |
|
|
Honoraria - 4SC; Agenus; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Grunenthal; Immunocore; Incyte; LEO Pharma; Merck Serono; Merck Sharp & Dohme; Mologen; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sysmex |
Consulting or Advisory Role - 4SC; Amgen; Bristol-Myers Squibb; Immunocore; Incyte; Merck Serono; Merck Sharp & Dohme; Mologen; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche/Genentech |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma; Takeda |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst) |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche; Sanofi/Aventis |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche; Sanofi/Aventis |
Research Funding - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Regeneron; Roche |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche; Sanofi/Aventis |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech |
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche |
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; OncoSec |
|
|
Honoraria - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche/Genentech |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche/Genentech |
Research Funding - Novartis (Inst); Roche/Genentech (Inst) |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD Oncology; Novartis; Pierre Fabre; Roche; Roche |
Speakers' Bureau - Bristol-Myers Squibb; Novartis |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess |
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess |
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech |
|
|
Consulting or Advisory Role - Incyte (Inst); MSD Oncology (Inst); Novartis (Inst) |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Roche |
|
|
Honoraria - Merck; Novartis |
Consulting or Advisory Role - Novartis; Pierre Fabre |
Speakers' Bureau - Merck; Novartis |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Pierre Fabre; Roche |
|
|
Honoraria - Bristol-Myers Squibb; MSD |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
|
Stock and Other Ownership Interests - Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
Consulting or Advisory Role - Amgen (Inst); TEVA (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Immunocore; Merck; Novartis; Roche |
Research Funding - Immunocore (Inst); Merck (Inst); Prometheus (Inst) |
|
|
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre |
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Incyte; MERCK; Novartis; OncoSec; Pierre Fabre |
Research Funding - BMS Brazil (Inst); Merck (Inst) |